A phase I study of MAT2501 for the treatment of for the treatment of non-tuberculous mycobacteria (NTM) infections
Phase of Trial: Phase I
Latest Information Update: 27 Mar 2017
At a glance
- Drugs Amikacin (Primary)
- Indications Gram-negative infections; Mycobacterial infections
- Focus Adverse reactions; Pharmacokinetics
- 27 Mar 2017 Topline results published in a Matinas BioPharma media release.
- 27 Mar 2017 Status changed from recruiting to completed, according to a Matinas BioPharma media release.
- 08 Mar 2017 According to a Matinas BioPharma media release, top line results from this trial will be reported in the coming weeks.